Adnan Aly Al Shofwan

Mr. Adnan Aly Al Shofwan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2022 in Cosmetics
Verified
Journal Article
Open access
PDF file
RPRimadani Pratiwi
Rimadani Pratiwi
NANisa Nurul Auliya AS
Nisa Nurul Auliya AS
RYRani Fitrilia Yusar
Rani Fitrilia Yusar
ASAdnan Aly Al Shofwan
Adnan Aly Al Shofwan
The general public uses cosmetics daily. Cosmetic products contain substances (ingredients) with various functions, from skincare to enhancing appearance, as well as ingredients that preserve the cosmetic products. Some cosmetic ingredients are prohibited or restricted in certain geographical regions, such as the European Union and the United States of America, due to their potential to cause adverse effects such as cancer, birth defects, and/or developmental and reproductive disorders. However, the ingredients may be used in other regions, and, hence, the monitoring of the cosmetic ingredients actually used is important to ensure the safety of cosmetic products. This review provides an overview of recent analytical methods that have been developed for detecting certain ingredients that are restricted or prohibited by the U.S. Food and Drug Administration (FDA) and/or EU legislation on cosmetic products.

3 March 2023 in Polymers
Verified
Journal Article
Open access
PDF file
ABArif Budiman
Arif Budiman
KKKalina Kalina
Kalina Kalina
LALevina Aristawidya
Levina Aristawidya
ASAdnan Aly Al Shofwan
Adnan Aly Al Shofwan
ARAgus Rusdin
Agus Rusdin
Diah Lia AulifaDiah Lia Aulifa
Diah Lia Aulifa
The addition of polymeric materials is often used to delay nucleation or crystal growth and maintain the high supersaturation of amorphous drugs. Therefore, this study aimed to investigate the impact of chitosan on the supersaturation behavior of drugs with a low recrystallization tendency and elucidate the mechanism of its crystallization inhibition in an aqueous solution. It was carried out using ritonavir (RTV) as a model of poorly water-soluble drugs categorized as class III of Taylor’s classification, while chitosan was used as a polymer, and hypromellose (HPMC) was used for comparison. The inhibition of the nucleation and crystal growth of RTV by chitosan was examined by measuring the induction time. The interactions of RTV with chitosan and HPMC were evaluated by NMR measurements, FT-IR, and an in silico analysis. The results showed that the solubilities of amorphous RTV with and without HPMC were quite similar, while the amorphous solubility was significantly increased by the chitosan addition due to the solubilization effect. In the absence of the polymer, RTV started to precipitate after 30 min, indicating that it is a slow crystallizer. Chitosan and HPMC effectively inhibited the nucleation of RTV, as reflected by a 48–64-fold enhancement in the induction time. Furthermore, NMR, FT-IR, and in silico analysis demonstrated that the hydrogen bond interaction between the amine group of RTV and a proton of chitosan, as well as the carbonyl group of RTV and a proton of HPMC, was observed. This indicated that the hydrogen bond interaction between RTV and chitosan as well as HPMC can contribute to the crystallization inhibition and maintenance of RTV in a supersaturated state. Therefore, the addition of chitosan can delay nucleation, which is crucial for stabilizing supersaturated drug solutions, specifically for a drug with a low crystallization tendency.